House panel seeks tighter price and margin controls for non-scheduled medicines
A parliamentary committee has urged stronger monitoring of medicine MRPs, trade margins and fixed-dose combinations, flagging that non-scheduled drugs account for 82% of India’s pharma market by value and remain outside direct price controls.
A parliamentary panel urged tighter price and trade-margin controls for non-scheduled medicines, citing weak DPCO coverage and high mark-ups. It sought permanent monitoring of MRPs, scrutiny of fixed-dose combinations, and details of drugs carrying mark-ups above 100%.
Why this matters
No related recent NPPA signals were provided. The committee recommendation raises scrutiny of medicine pricing and margins in the largely uncontrolled non-scheduled drug market.
Retail-company signals are accelerating, up 397533% QoQ.